📗 Cite This Artifact
CSF2RA — Colony Stimulating Factor 2 Receptor Alpha Chain
CSF2RA — Colony Stimulating Factor 2 Receptor Alpha Chain
Introduction
CSF2RA (Colony Stimulating Factor 2 Receptor Alpha Chain) encodes the alpha chain of the granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor. This heterodimeric receptor consists of a ligand-specific alpha chain (CSF2RA) that binds GM-CSF with low affinity, and a common beta chain (CSF2RB) that amplifies signaling and confers high-affinity binding. The receptor is expressed on hematopoietic cells, particularly myeloid lineages, and plays essential roles in cell survival, proliferation, differentiation, and functional activation["@miyajima1998"][@nicola1993].
CSF2RA — Colony Stimulating Factor 2 Receptor Alpha Chain
Introduction
CSF2RA (Colony Stimulating Factor 2 Receptor Alpha Chain) encodes the alpha chain of the granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor. This heterodimeric receptor consists of a ligand-specific alpha chain (CSF2RA) that binds GM-CSF with low affinity, and a common beta chain (CSF2RB) that amplifies signaling and confers high-affinity binding. The receptor is expressed on hematopoietic cells, particularly myeloid lineages, and plays essential roles in cell survival, proliferation, differentiation, and functional activation["@miyajima1998"][@nicola1993].
Beyond its well-established role in hematopoiesis, GM-CSF signaling has emerged as a critical pathway in neuroinflammation and neurodegenerative diseases. Microglia, the resident immune cells of the brain, express functional GM-CSF receptors, and CSF2RA signaling influences microglial activation states, cytokine production, and phagocytic activity. This has made the GM-CSF pathway a focus of research in Alzheimer's disease, Parkinson's disease, multiple sclerosis, and other neuroinflammatory conditions["@hamilton2020"][@wicks2022].
Gene Overview
<div class="infobox infobox-gene">
<div class="infobox-header">CSF2RA Gene</div>
<div class="infobox-row">
<div class="infobox-label">Gene Symbol</div>
<div class="infobox-value">CSF2RA</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Full Name</div>
<div class="infobox-value">Colony Stimulating Factor 2 Receptor Alpha Chain</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Chromosomal Location</div>
<div class="infobox-value">Xp22.32</div>
</div>
<div class="infobox-row">
<div class="infobox-label">NCBI Gene ID</div>
<div class="infobox-value"><a href="https://www.ncbi.nlm.nih.gov/gene/1442" target="_blank">1442</a></div>
</div>
<div class="infobox-row">
<div class="infobox-label">OMIM</div>
<div class="infobox-value"><a href="https://www.omim.org/entry/306010" target="_blank">306010</a></div>
</div>
<div class="infobox-row">
<div class="infobox-label">Ensembl ID</div>
<div class="infobox-value">ENSG00000198211</div>
</div>
<div class="infobox-row">
<div class="infobox-label">UniProt ID</div>
<div class="infobox-value">P15509</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Gene Family</div>
<div class="infobox-value">Type I cytokine receptor family, GM-CSF receptor family</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Inheritance</div>
<div class="infobox-value">Autosomal (pseudoautosomal region of X chromosome)</div>
</div>
</div>
Receptor Structure and Signaling
Structural Organization
The GM-CSF receptor complex consists of two subunits[@miyajima1998]:
| Subunit | Gene | Function |
|---------|------|----------|
| Alpha chain (CD116) | CSF2RA | Ligand binding, low-affinity receptor |
| Beta chain (CD131) | CSF2RB | Signal transduction, high-affinity complex |
The alpha chain is a Type I transmembrane protein with:
- Extracellular domain: Contains cytokine receptor homology (CRH) modules
- Transmembrane domain: Single pass helix
- Cytoplasmic domain: ~90 amino acids, minimal signaling capability
The beta chain, encoded by CSF2RB, is shared with the IL-3 and IL-5 receptor complexes. It provides the majority of the cytoplasmic signaling capacity and converts the low-affinity alpha chain into a high-affinity receptor when co-expressed.
Signaling Pathways
GM-CSF binding activates multiple downstream signaling cascades:
| Pathway | Key Molecules | Cellular Outcomes |
|---------|---------------|-------------------|
| JAK2-STAT5 | JAK2, STAT5A/B | Gene transcription, cell survival |
| RAS-MAPK | RAS, RAF, MEK, ERK | Proliferation, differentiation |
| PI3K-AKT | PI3K, AKT, mTOR | Survival, metabolism |
| PLCγ | PLCγ, PKC | Calcium signaling, activation |
The beta chain contains multiple tyrosine residues that serve as docking sites for STAT5 and other signaling proteins. JAK2 constitutively associated with the beta chain becomes activated upon ligand binding, leading to STAT5 phosphorylation and dimerization[nicol a1993].
Receptor Expression
Cellular Distribution
| Cell Type | Expression Level | Notes |
|-----------|------------------|-------|
| Monocytes/Macrophages | High | Primary expressors |
| Neutrophils | Moderate | Lower than monocytes |
| Dendritic Cells | High | Critical for immune function |
| Microglia | Moderate | Brain-resident macrophages |
| Neural Progenitor Cells | Low | Developmental expression |
| Some Epithelial Cells | Variable | Tissue-specific |
Biological Functions
Hematopoietic Functions
1. Myeloid Cell Development
GM-CSF stimulates the production and differentiation of:
- Granulocytes (neutrophils, eosinophils, basophils)
- Macrophages
- Dendritic cells
GM-CSF is considered a "myeloid" cytokine due to its broad effects on multiple myeloid lineages[gough1985].
2. Cell Survival and Proliferation
GM-CSF promotes survival of myeloid precursor cells and drives proliferation in response to cytokine signaling.
3. Functional Activation
GM-CSF activates mature myeloid cells, enhancing:
- Phagocytic activity
- Cytokine production
- Antigen presentation
- Microbial killing
Neurobiological Functions
1. Microglial Regulation
Microglia express CSF2RA and respond to GM-CSF signaling[@smith2023][@nguyen2023]:
- Pro-inflammatory activation: GM-CSF can drive microglial production of pro-inflammatory cytokines (IL-1β, TNF-α, IL-6)
- Anti-inflammatory polarization: Under certain conditions, GM-CSF can promote neuroprotective microglial phenotypes
- Phagocytosis: GM-CSF enhances microglial phagocytosis of debris and pathogens
- Neurotrophic factor production: Activated microglia produce BDNF and other neuroprotective factors
During CNS development, GM-CSF signaling may influence:
- Neural progenitor cell proliferation and differentiation
- Microglial colonization of the brain
- Synapse formation and remodeling
GM-CSF enables microglial responsiveness to CNS injury and infection, making it critical for immune surveillance of the brain[prita2019].
Disease Associations
Alzheimer's Disease
GM-CSF/CSF2RA signaling plays complex roles in Alzheimer's disease pathogenesis[@smith2023]:
Microglial Responses to Amyloid
- GM-CSF enhances microglial phagocytosis of amyloid-beta plaques
- Chronic GM-CSF signaling may contribute to neurotoxic microglial activation
- Modulation of GM-CSF signaling is being explored as a therapeutic strategy
- Recombinant GM-CSF (sargramostim) has been tested in clinical trials for AD
- Phase I/II studies showed some cognitive benefit in mild AD patients
- Mechanistically, GM-CSF may enhance plaque clearance via microglia
- Some studies suggest CSF2RA variants influence AD risk
- The X-chromosome location may contribute to sex-specific disease patterns
Parkinson's Disease
GM-CSF signaling affects dopaminergic neuron survival and neuroinflammation in PD[@liu2022]:
Neuroinflammation Modulation
- GM-CSF promotes microglial activation in the substantia nigra
- Activated microglia release pro-inflammatory cytokines that damage dopaminergic neurons
- Blocking GM-CSF signaling has shown neuroprotective effects in PD models
- GM-CSF can support survival of dopaminergic neurons under certain conditions
- The cytokine may have both beneficial (neurotrophic) and detrimental (pro-inflammatory) effects
- CSF2RA antagonists are being investigated for PD treatment
- Targeting microglial activation via GM-CSF blockade may reduce neuroinflammation
Multiple Sclerosis
GM-CSF is a key driver of neuroinflammation in MS[@baron2020][@wicks2022]:
Pathogenic Role
- GM-CSF promotes pro-inflammatory T cell responses
- Drives microglial activation in CNS lesions
- Contributes to demyelination and axonal injury
- Lenzilumab: Anti-GM-CSF monoclonal antibody tested in MS trials
- GM-CSF receptor antagonists: Block signaling to reduce inflammation
- Clinical trials have shown some benefit in reducing MS disease activity
- CSF2RA variants have been linked to MS susceptibility
- The X-chromosome location may explain some aspect of female predominance in MS[gilden2021]
Amyotrophic Lateral Sclerosis (ALS)
Emerging evidence suggests GM-CSF signaling in ALS pathogenesis[@rosenberg2021]:
- Microglial activation in ALS is partially driven by GM-CSF
- Some CSF2RA variants may influence ALS risk
- Targeting GM-CSF is under investigation as a therapeutic strategy
Pulmonary Alveolar Proteinosis (PAP)
While primarily a lung disease, PAP provides insight into CSF2RA function[@martinezmoczygemba2007][@trapnell2009]:
- CSF2RA deficiency leads to impaired alveolar macrophage function
- GM-CSF is essential for surfactant clearance by alveolar macrophages
- Autoantibodies against GM-CSF cause adult-onset PAP
Other Conditions
| Condition | Association |
|-----------|-------------|
| Rheumatoid Arthritis | CSF2RA variants associated with disease susceptibility |
| Autoimmune Hepatitis | GM-CSF-driven inflammation |
| Cancer Immunotherapy | GM-CSF used to enhance immune responses |
Therapeutic Implications
GM-CSF-Based Therapies
Recombinant GM-CSF (Sargramostim)
- Used to stimulate neutrophil production in chemotherapy-induced neutropenia
- Tested in Alzheimer's disease clinical trials
- May enhance immune surveillance and plaque clearance
Targeting CSF2RA
Antagonists and Blocking Agents
- Lenzilumab: Humanized anti-GM-CSF antibody
- GM-CSF receptor fusion proteins: Decoy receptors
- Small molecule inhibitors: Under development
| Disease | Strategy | Status |
|---------|----------|--------|
| Multiple Sclerosis | Anti-GM-CSF antibodies | Phase 2 trials |
| Rheumatoid Arthritis | CSF2RA antagonists | Approved (mavrilimumab) |
| Alzheimer's Disease | GM-CSF modulation | Phase 1/2 trials |
| Parkinson's Disease | GM-CSF blockade | Preclinical |
Microglial Modulation
Approaches to modulate microglial function via CSF2RA include[@wan2023]:
- Agonists: Enhance neuroprotective microglial phenotypes
- Antagonists: Reduce pro-inflammatory activation
- Selective modulators: Bias signaling toward beneficial pathways
Genetic Considerations
X-Chromosome Location
CSF2RA is located on the X chromosome pseudoautosomal region, meaning:
- It escapes X-inactivation in females
- Males have a single allele (hemizygous)
- This may contribute to sex differences in immune responses
Variant Effects
| Variant Type | Example | Effect |
|--------------|---------|--------|
| Loss-of-function | Nonsense/frameshift | Severe immunodeficiency |
| Missense | Point mutations | Variable functional impairment |
| Polymorphisms | Common variants | Altered disease susceptibility |
Expression in Neurodegeneration
Microglial Activation States
CSF2RA expression and GM-CSF signaling influence microglial phenotype:
| Activation State | GM-CSF Effect | Net Outcome |
|-----------------|---------------|-------------|
| M1 (pro-inflammatory) | Enhanced | Neurotoxic |
| M2 (anti-inflammatory) | Variable | Potentially neuroprotective |
| Disease-associated | Driver | Progressive degeneration |
Aging and Neurodegeneration
CSF2RA expression changes in the aging brain[@mueller2022]:
- Microglial GM-CSF receptor expression increases with age
- This may contribute to age-related neuroinflammation
- Altered signaling may promote neurodegenerative processes
Research Directions
Key Questions
Emerging Areas
- Single-cell analysis: Defining CSF2RA-expressing cell populations in the brain[nguyen2023]
- Brain region specificity: Understanding regional differences in GM-CSF responsiveness
- Combination therapies: Targeting GM-CSF with other immune modulators
- Personalized medicine: Genetic variants as predictors of therapeutic response
External Links
- [NCBI Gene: CSF2RA](https://www.ncbi.nlm.nih.gov/gene/1442)
- [UniProt: CSF2RA (P15509)](https://www.uniprot.org/uniprot/P15509)
- [OMIM: 306010](https://www.omim.org/entry/306010)
- [Human Protein Atlas: CSF2RA](https://www.proteinatlas.org/)
- [ClinicalTrials.gov: GM-CSF](https://clinicaltrials.gov/search?term=GM-CSF)
See Also
- [GM-CSF](/entities/gm-csf)
- [CSF2RB](/genes/csf2rb)
- [Multiple Sclerosis](/diseases/multiple-sclerosis)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Microglia](/cell-types/microglia)
- [Neuroinflammation](/mechanisms/neuroinflammation)
- [Cytokine Signaling](/mechanisms/cytokine-signaling)
References
Pathway Diagram
The following diagram shows the key molecular relationships involving CSF2RA — Colony Stimulating Factor 2 Receptor Alpha Chain discovered through SciDEX knowledge graph analysis:
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | genes-csf2ra |
| kg_node_id | CSF2RA |
| entity_type | gene |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-3dda1490d846 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'genes-csf2ra'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-genes-csf2ra?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[CSF2RA — Colony Stimulating Factor 2 Receptor Alpha Chain](http://scidex.ai/artifact/wiki-genes-csf2ra)
http://scidex.ai/artifact/wiki-genes-csf2ra